Experience
Duchesnay Inc.
Actavis Laboratories FL, Inc.
Represented Duchesnay in ANDA litigation in the District of Delaware against multiple generic drug manufacturers seeking to make a generic version of Bonjesta® (doxylaine succinate and phyridoxine hydrochloride) for the treatment of nausea and vomiting in pregnancy.
Duchesnay Inc. v. Actavis Laboratories FL, Inc., 1:18-cv-01895, D. Del., Judges Andrews, Fallon
Eli Lilly and Company v. Actavis Labs. UT Inc.
Eli Lilly and Company
Finnegan secures 10 years of patent protection for Relistor®
Valeant; Salix; Progenics
BioDelivery Sciences International, Inc. et al. v. Alvogen PB Research & Development LLC et al.
BioDelivery Sciences International, Inc. et al.
NICE Ltd. et al v. CallMiner Inc.
NICE Ltd. et al
Aerin Medical Inc. et al. v. Neurent Medical Inc. et al.
Aerin Medical Inc. et al.
AbbVie Inc.
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.
Sarepta Therapeutics, Inc. et al.
Abbott Laboratories v. Teva Pharmaceuticals USA, Inc.
Abbott Laboratories
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.